Second-line treatment of small-cell lung cancer

MacCallum, Cecilia; Gillenwater, Heidi H.

doi:10.1007/s11912-006-0030-8

Cited by 13 publications

(7 citation statements)

References 27 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the only second-line treatment for SCLC approved by the US Food and Drug Administration (FDA) is topotecan [30,31]. Several studies have evaluated potential alternatives to topotecan in this indication.…”

Section: Discussionmentioning

confidence: 99%

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

Eisen

Thatcher

Leyvraz³

et al. 2009

Lung Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

Eisen

Thatcher

Leyvraz³

et al. 2009

Lung Cancer

View full text Add to dashboard Cite

“…Irinotecan has international regulatory approval for use in the treatment of colorectal cancer and is active against a wide variety of solid tumors. [1][2][3][4][5] Much is known about the drug's metabolism and pharmacokinetics. The hydrolysis of irinotecan by the high-affinity carboxylesterase-2 is responsible for activation of irinotecan to SN-38 (7-ethyl-10-hydroxycamptothecin), a potent topoisomerase I inhibitor.…”

mentioning

confidence: 99%

Pharmacogenetic Pathway Analysis of Irinotecan

Rosner

Panetta

Innocenti

et al. 2008

Clin Pharmacol Ther

View full text Add to dashboard Cite

Irinotecan, a chemotherapeutic agent for various solid tumors, is a prodrug requiring activation to SN-38. Irinotecan's complex pharmacokinetics allows for potentially many genetic sources of variability. We explored relationships between pharmacokinetic pathways and polymorphisms in genes associated with irinotecan's metabolism and transport. We fit a seven-compartment pharmacokinetic model with enterohepatic recirculation to concentrations of irinotecan and metabolites SN-38, SN-38G (glucuronide), and APC. Principal component analysis (PCA) of patientspecific parameter estimates produced measures interpretable along pathways. Nine principal components characterized overall variation well. Polymorphisms in genes UGT1A1, UGT1A7, and UGT1A9 had strong associations with a component corresponding to the irinotecan-to-SN-38 pathway and SN-38 recirculation and to a component relating to SN-38-to-SN-38G conversion and SN-38G's elimination. The component characterizing irinotecan's compartments was associated with HNF1α and ABCC2 polymorphisms. The exploratory analysis with PCA in this pharmacogenetic analysis identified known associations and may have allowed identification of previously uncharacterized functional polymorphisms.

show abstract

“…Clinical studies have shown that no therapy significantly improved the 15–20% response rate (RR) provided by second-line topotecan (the only drug with official approval in second line). Topotecan proved its efficacy regarding patients' response to therapy, safety, and symptom palliation in many phase II studies [11, 12]. The randomized multicenter phase III study on topotecan versus cyclophosphamide, doxorubicin, and vincristine (CAV) in patients with SCLC who progressed at least 60 days after completion of first-line therapy showed that topotecan was at least equally effective as CAV and led to its approval by the FDA [11, 12].…”

Section: Introductionmentioning

confidence: 99%

The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature

Tsiouprou

Zaharias

Spyratos

2019

Canadian Respiratory Journal

View full text Add to dashboard Cite

Lung cancer is the second most common cancer in both sexes worldwide. Small-cell lung cancer (SCLC) is a form of neuroendocrine tumor, which is classified into limited and extensive-stage disease and shows excellent initial response to chemotherapy; however, almost all patients relapse later. During the past few years, several clinical trials have evaluated the effect of addition of immunotherapy to conventional chemotherapy in patients with extensive SCLC. Checkpoint inhibitors are currently under investigation, especially the CTLA-4 and PD-1/PD-L1 inhibitors. Nowadays, evidence show a statistically significant survival benefit of adding atezolizumab, an IgG1 monoclonal antibody targeting against PD-L1, to platinum-based chemotherapy plus etoposide in patients who have not received any previous systemic therapy. Furthermore, the role of nivolumab, an IgG4 anti-PD-1 monoclonal antibody, is significant for the treatment of relapsed SCLC cases. Recently, pembrolizumab was the first immunotherapeutic agent to be approved by the FDA for patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy and at least one other prior line of chemotherapy. Nevertheless, prognostic biomarkers to immunotherapy response remain to be discovered.

show abstract

Second-line treatment of small-cell lung cancer

Cited by 13 publications

References 27 publications

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

Pharmacogenetic Pathway Analysis of Irinotecan

The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature

Contact Info

Product

Resources

About